KRYS earnings date and last-quarter result: next report 2026-08-03, last quarter beat, P/E 43.46. Updated 2026-07-23.
Krystal Biotech (KRYS) Research Hub
Krystal Biotech (KRYS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 313.66 USD (+0.69%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 43.46, market cap 9.99B. This hub links to the full technical, earnings and options research available for KRYS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 313.66 USD (+0.69%) |
| 52-week range | 309.63 USD – 382.54 USD |
| Trend regime | Range |
| 14-day RSI | 40.5 (Bearish) |
| Trailing P/E | 43.46 |
| Market cap | 9.99B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for KRYS
Covered Call on KRYS: how it works, illustrative setup around the real 313.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KRYS: how it works, illustrative setup around the real 313.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KRYS: how it works, illustrative setup around the real 313.66 USD price, max profit/loss, breakeven and when to use it. Educational.
KRYS technical analysis: range, last 313.66 USD, RSI 40.5, 52w range 309.63 USD–382.54 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is KRYS in?
Krystal Biotech (KRYS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KRYS in an uptrend or downtrend?
As of 2026-10-26, KRYS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KRYS's trailing P/E ratio?
KRYS's trailing P/E is 43.46, with a market cap of 9.99B. See the earnings research page for full valuation detail.
When does KRYS next report earnings?
KRYS is next scheduled to report earnings on 2026-08-03.